The culture at our Biberach facility reflects a unique philosophy: it is purposely designed to encourage free-thinking, cross-functional and global collaboration. We grow on the vision necessary to drive scientific and operational excellence. And we deliver breakthrough medicines, out of Biberach, with our partners worldwide. We are passionate about first in class medications by focusing on the unmet need of patients. From over 100 projects in our current pipeline, some emblematic examples below showcase our pioneering creative spirit and patient-centric approach.
OFEV® (Nintedanib) Our receptor tyrosine kinase inhibitor, for the treatment of patients e.g. with idiopathic pulmonary fibrosis or systemic sclerosis-associated interstitial lung disease.
Jardiance® (Empagliflozin). Our SGLT2-inhibitor for the treatment for adults with type 2 diabetes mellitus, e.g. as an adjunct to diet and exercise to improve glycemic control and to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Spiriva® (Tiotropium Bromide). Our muscarinic antagonist, e.g. for the maintenance treatment of patients with chronic obstructive pulmonary disease.
Sifrol® (Pramipexol). Our dopamine agonist for the treatment of patients with idiopathic Parkinson´s disease e.g. as monotherapy.
An outstanding current track record of 19 launched biologics out of our facilities in Biberach reflects what is unique about our flagship site: we treat our customers’ products as if they were our own and this drives us to truly live a collaborative spirit. It is relevant for projects with our global customer base of top 20 pharmaceutical companies and innovative biotechs as well as for all Boehringer Ingelheim biologics (e.g. Metalyse® or Actilyse®).
More information can be found in our Annual Report